• In recent months, Baxter International has completed the divestiture of its Kidney Care business and reported modest sales growth with improving operating cash flow, underscoring progress after its portfolio simplification.
• This tighter focus on a medtech and hospital-products platform with a large installed base and recurring consumables demand is sharpening attention on margin improvement and cash conversion across the remaining business.
• Next, we’ll explore how Baxter’s sharpened post-restructuring focus on profitability and cash generation shapes its investment narrative for investors.

Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

Baxter International Investment Narrative Recap

To own Baxter today, you need to believe that its streamlined medtech and hospital-products focus can translate into better margins and stronger cash generation after years of weak returns. The Kidney Care divestiture and improving operating cash flow support that thesis but do not remove the key near term risk that margin execution could disappoint if cost reductions and mix shifts do not keep pace with the leaner portfolio.

Among recent announcements, the Q1 2026 results and reiterated outlook are most relevant here, as they pair modest sales growth with improved operating cash flow while still reflecting a net loss. For investors watching Baxter’s turnaround, this combination puts more weight on how quickly the company can convert its large installed base and recurring consumables into sustainable profitability and stronger balance sheet flexibility.

Yet beneath the apparent progress, investors should be aware that margin pressure from mix shifts and stranded costs could still...

Baxter International's narrative projects $12.1 billion revenue and $629.2 million earnings by 2029. This requires 2.2% yearly revenue growth and a $1.61 billion earnings increase from -$981.0 million.

Uncover how Baxter International's forecasts yield a $21.54 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were previously assuming Baxter could reach about US$12.1 billion in revenue and US$766.3 million in earnings, yet the latest results and margin focus may prompt you to question whether those upside scenarios, especially around faster IV Solutions recovery, still hold or need revisiting as new information emerges.

Explore 6 other fair value estimates on Baxter International - why the stock might be worth as much as 63% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Baxter International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Baxter International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Baxter International's overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.